Regulatory & Compliance

Evolving Trends and Innovations in Acute Coronary Syndrome Care
Management & Regulatory Evolving Trends and Innovations in Acute Coronary Syndrome Care

The field of acute coronary syndrome (ACS) care has witnessed significant advancements, driven by an evolving understanding of patient management practices and continuous clinical research efforts. These innovations encompass various aspects of treatment, from rethinking established protocols like

UAE to Lead Affordable CAR-T Therapy with New Biomanufacturing Hub
Biotech & Bioprocessing UAE to Lead Affordable CAR-T Therapy with New Biomanufacturing Hub

In a groundbreaking initiative, Burjeel Holdings is joining forces with Caring Cross to establish advanced biomanufacturing facilities dedicated to chimeric antigen receptor (CAR)-T cell therapies in the United Arab Emirates (UAE). This collaboration aims to revolutionize the production and

Is Columvi the Game-Changer for Refractory DLBCL Treatment?
Management & Regulatory Is Columvi the Game-Changer for Refractory DLBCL Treatment?

Roche's Columvi, a bispecific antibody known as glofitamab, has been approved by the European Commission (EC) for use in combination with gemcitabine and oxaliplatin (GemOx) to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults who are not candidates for autologous stem

Navigating Medtech Challenges: Regulatory, Reshoring, and Tech Gaps
Management & Regulatory Navigating Medtech Challenges: Regulatory, Reshoring, and Tech Gaps

The medical and life sciences manufacturing sector is experiencing rapid transformations, bringing forth a plethora of challenges and opportunities for industry professionals. Ascential's "2025 State of Medical & Life Sciences Manufacturing" report delves into key areas such as regulatory

Will Mehmet Oz Revolutionize Telehealth with New CMS Policies?
Management & Regulatory Will Mehmet Oz Revolutionize Telehealth with New CMS Policies?

The rapid advancements in telehealth have been met with a mixture of enthusiasm and concern, especially as regulatory frameworks struggle to keep pace with technological innovations. At the center of this challenge is Mehmet Oz, the newly appointed Administrator of the Centers for Medicare &

Novartis' Vanrafia Approved by FDA for Rare Kidney Disease Treatment
Management & Regulatory Novartis' Vanrafia Approved by FDA for Rare Kidney Disease Treatment

Ivan Kairatov is a recognized authority in the biopharma sector, with an extensive background in technological advancements and R&D. In this interview, Ivan shares his insights on the new FDA-approved treatment for IgA nephropathy (IgAN), shedding light on its significance in treating this rare

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later